PREDICTORS OF DEEP MOLECULAR RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH IMATINIB MESYLATE: AN ANALYSIS BY THE GIMEMA CML WP

被引：0

作者：

Castagnetti, F. ^{[1
]}

Gugliotta, G. ^{[1
]}

Breccia, M. ^{[2
]}

Specchia, G. ^{[3
]}

Binotto, G. ^{[4
]}

Abruzzese, E. ^{[5
]}

Iurlo, A. ^{[6
]}

Vigneri, P. ^{[7
]}

Cavazzini, F. ^{[8
]}

Intermesoli, T. ^{[9
]}

Ferrero, D. ^{[10
]}

Martino, B. ^{[11
]}

Leoni, P. ^{[12
]}

Bocchia, M. ^{[13
]}

Rege-Cambrin, G. ^{[14
]}

Gherlinzoni, F. ^{[15
]}

Bochicchio, M. T. ^{[1
]}

Soverini, S. ^{[1
]}

Alimena, G. ^{[2
]}

Pane, F. ^{[16
]}

Saglio, G. ^{[14
]}

Cavo, M. ^{[1
]}

Martinelli, G. ^{[1
]}

Baccarani, M. ^{[17
]}

Rosti, G. ^{[1
]}

机构：

[1] Univ Bologna, Inst Hematol L&A Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[2] Univ Roma La Sapienza, Chair Hematol, I-00185 Rome, Italy

[3] Univ Bari, Chair Hematol, Bari, Italy

[4] Univ Padua, Chair Hematol, Padua, Italy

[5] S Eugenio Hosp, Hematol Unit, Rome, Italy

[6] Fdn IRCCS Ca Granda Osped Maggiore, Hematol Unit, Milan, Italy

[7] Univ Catania, Chair Hematol, Catania, Italy

[8] Univ Ferrara, Chair Hematol, I-44100 Ferrara, Italy

[9] Osped Riuniti Bergamo, Hematol Unit, I-24100 Bergamo, Italy

[10] Univ Turin, Chair Hematol, Turin, Italy

[11] Osped Riuniti Reggio Calabria, Hematol Unit, Reggio Di Calabria, Italy

[12] Torrette Univ Hosp, Chair Hematol, Ancona, Italy

[13] Univ Siena, Chair Hematol, I-53100 Siena, Italy

[14] S Luigi Gonzaga Univ Hosp, Chair Hematol, Orbassano, TO, Italy

[15] Ca Foncello Hosp, Hematol Unit, Treviso, Italy

[16] Univ Naples Federico II, Chair Hematol, Naples, Italy

[17] Univ Bologna, Dept Hematol & Oncol L&A Seragnoli, Bologna, Italy

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

S810

引用

页码：324 / 324

页数：1

共 50 条

[31] Cytogenetic responses in chronic myeloid leukemia patients treated with imatinib mesylate
Babameto-Laku, A.
Mokin, V.
Cikuli, M.
Xhumari, P.
CHROMOSOME RESEARCH, 2005, 13 : 158 - 158
[32] Nutritional Status of Patients with Chronic Myeloid Leukemia Treated with Imatinib Mesylate
Jose Castillo-Martinez, Maria
Juventina Tuna-Aguilar, Elena
del Pilar Milke-Garcia, Maria
Camacho Zamora, Anais
Villegas Cervantes, Viviana
Castillo-Martinez, Lilia
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2022, 74 (09): : 3211 - 3216
[33] Sudden blastic transformation (SBT) in patients (pts) with chronic myeloid leukemia (CML) treated with imatinib mesylate.
Vidal, M
Kantarjian, H
O'Brien, S
Rios, MB
Verstovsek, S
Cortes, J
BLOOD, 2004, 104 (11) : 801A - 801A
[34] Multicenter experience with imatinib, mesylate in newly diagnosed chronic myeloid leukemia (CML) patients
Carella, A. M.
Lerma, E.
Orlandi, E.
Lazzarino, M.
Annunziata, M.
Ferrara, F.
Pungolino, E.
Morra, E.
Miglino, M.
Gobbi, M.
BLOOD, 2007, 110 (11) : 210B - 210B
[35] PREDICTORS OF STABLE DEEP MOLECULAR RESPONSE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH DASATINIB OR NILOTINIB AFTER IMATINIB FAILURE
Bonifacio, M.
Binotto, G.
Tiribelli, M.
Scaffidi, L.
Iurlo, A.
Cibien, F.
Maino, E.
Guella, A.
Festini, G.
Minotto, C.
De Biasi, E.
Frison, L.
De Marchi, F.
Medeot, M.
Bucelli, C.
Calistri, E.
Stulle, M.
Gherlinzoni, F.
Cortelezzi, A.
Fanin, R.
Semenzato, G.
Krampera, M.
Pizzolo, G.
Ambrosetti, A.
HAEMATOLOGICA, 2016, 101 : S74 - S74
[36] Imatinib mesylate in chronic myeloid leukemia (CML): A single institution experience of 174 patients
Deshmukh, CD
Saikia, T
Bakshi, AV
Parikh, PM
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 610S - 610S
[37] Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis
Gugliotta, Gabriele
Castagnetti, Fausto
Breccia, Massimo
D'Adda, Mariella
Stagno, Fabio
Levato, Luciano
Carella, Angelo Michele
Martino, Bruno
Tiribelli, Mario
Rege-Cambrin, Giovanna
Gozzini, Antonella
Salvucci, Marzia
Cedrone, Michele
Trabacchi, Elena
Usala, Emilio
Scortechini, Anna Rita
Luciano, Luigia
Soverini, Simona
Cavo, Michele
Martinelli, Giovanni
Pane, Fabrizio
Saglio, Giuseppe
Baccarani, Michele
Rosti, Gianantonio
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S313 - S314
[38] Monitoring response and treatment outcome in patients with chronic phase chronic myeloid leukemia (CML) treated with imatinib
Teitelbaum, A.
Spencer, D.
Bollu, V. K.
Chastek, B.
Coombs, J.
Kulakodlu, M.
Morlock, R.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[39] How long will chronic myeloid leukemia patients treated with imatinib mesylate live?
Hasford, J
Pfirrmann, M
Hochhaus, A
LEUKEMIA, 2005, 19 (04) : 497 - 499
[40] Factors influencing physician recommendation for imatinib mesylate in chronic phase chronic myeloid leukemia (CML) patients
Iyer, SS
Doucette, WR
VALUE IN HEALTH, 2004, 7 (03) : 247 - 247

← 1 2 3 4 5 →